With landmark FDA approval, Novartis wins race to market CAR T-cell therapy

Switzerland’s Novartis (NOV: N) has won the race to market a CAR T-cell-directed therapy, receiving US Food and Drug Administration approval for its Kymriah (tisagenlecleucel) infusion.

It’s also the first US FDA-approved therapy based on gene transfer technology.

Kymriah is approved to treat patients with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.